NASDAQ : WVE
Wave Life Sciences Ltd. — Key statistics
Healthcare · Biotechnology · Singapore
Last price 3.59 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 708.05M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 695.23M |
| Enterprise Value | 307.49M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 197.23M |
| Shares Outstanding | 197.23M |
| Shares Change (YoY) | +20.23% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 0.43% |
| Owned by Institutions (%) | 64.94% |
| Float | 94.71M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.98 |
| Forward PS | 24.47 |
| PB Ratio | 1.76 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.38 |
| Quick Ratio | 8.09 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -78.80% |
| Return on Assets (ROA) | -37.97% |
| Return on Invested Capital (ROIC) | -47.63% |
| Return on Capital Employed (ROCE) | -50.23% |
| Weighted Average Cost of Capital (WACC) | -3.40% |
| Revenue Per Employee | $223,726 |
| Profits Per Employee | -$664,142 |
| Employee Count | 317 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -1.43 |
| 52-Week Price Change | -59.90% |
| 50-Day Moving Average | 4.03 |
| 200-Day Moving Average | 7.37 |
| Relative Strength Index (RSI) | 50.41 |
| Average Volume (20 Days) | 2,883,006 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 21.17M |
| Short Previous Month | 18.56M |
| Short % of Shares Out | 10.73% |
| Short % of Float | 22.35% |
| Short Ratio (days to cover) | 6.51 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 70.92M |
| Gross Profit | -134.47M |
| Operating Income | -227.61M |
| Pretax Income | -210.53M |
| Net Income | -210.53M |
| EBITDA | -224.19M |
| EBIT | -227.61M |
| Loss Per Share | -$1.07 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 430.75M |
| Total Debt | 43.27M |
| Net Cash | 387.74M |
| Net Cash Per Share | $1.97 |
| Equity (Book Value) | 401.94M |
| Book Value Per Share | 2.04 |
| Working Capital | 403.87M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -207.05M |
| Capital Expenditures | -1.34M |
| Depreciation & Amortization | 3.42M |
| Net Borrowing | n/a |
| Free Cash Flow | -208.39M |
| FCF Per Share | -$1.06 |
Margins
| Measure | Value |
|---|
| Gross Margin | -189.60% |
| Operating Margin | -320.94% |
| Pretax Margin | -296.86% |
| Profit Margin | -296.86% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -20.23% |
| Shareholder Yield | -20.23% |
| Earnings Yield | -30.29% |
| FCF Yield | -29.43% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.11 |
| Price Target Difference | 385.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (3Y) | 14.42% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 4.61 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |